It won't be long before Zealand Pharma sends a drug on the market for the first time. Analysts deem that this might generate a billion-kroner income, according to Danish newspaper Børsen.
Last month, the biotech company received approval for the drug dasiglucagon, which will be marketed by the name of Zegalogue with the US Food and Drug Administration (FDA).
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.